The importance of co‐delivery of nanoparticle‐siRNA and anticancer agents in cancer therapy

Khelghati, Nafiseh; Mokhtarvand, Jafar Soleimanpour; Mir, Mostafa; Alemi, Forough; Asemi, Zatollah; Sadeghpour, Alireza; Maleki, Masomeh; Kafil, Hossein Samadi; Jadidi‐Niaragh, Farhad; Majidinia, Maryam; Yousefi, Bahman

doi:10.1111/cbdd.13824

Cited by 14 publications

(7 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Knocking out key genes involved in apoptotic processes and the cell cycle is one of the essential ways in cancer therapy. Hence, siRNA is a promising candidate for inhibiting tumor development and invasion [ 69 ]. Combining siRNA therapy with chemotherapeutic drugs can overcome multidrug resistance and promote apoptosis [ 70 ].…”

Section: Combination Of Ici Therapy With Chemotherapymentioning

confidence: 99%

Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy

Kiaie,

Salehi-Shadkami,

Sanaei

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

Immune checkpoint (ICP) molecules expressed on tumor cells can suppress immune responses against tumors. ICP therapy promotes anti-tumor immune responses by targeting inhibitory and stimulatory pathways of immune cells like T cells and dendritic cells (DC). The investigation into the combination therapies through novel immune checkpoint inhibitors (ICIs) has been limited due to immune-related adverse events (irAEs), low response rate, and lack of optimal strategy for combinatorial cancer immunotherapy (IMT). Nanoparticles (NPs) have emerged as powerful tools to promote multidisciplinary cooperation. The feasibility and efficacy of targeted delivery of ICIs using NPs overcome the primary barrier, improve therapeutic efficacy, and provide a rationale for more clinical investigations. Likewise, NPs can conjugate or encapsulate ICIs, including antibodies, RNAs, and small molecule inhibitors. Therefore, combining the drug delivery system (DDS) with ICP therapy could provide a profitable immunotherapeutic strategy for cancer treatment. This article reviews the significant NPs with controlled DDS using current data from clinical and pre-clinical trials on mono- and combination IMT to overcome ICP therapeutic limitations.

show abstract

Section: Combination Of Ici Therapy With Chemotherapymentioning

confidence: 99%

Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy

Kiaie,

Salehi-Shadkami,

Sanaei

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…The incentive behind the co-delivery of genes and chemotherapeutic drugs is to disrupt MDR signaling pathways [ 95 , 140 ]. This disruption helps overcome MDR in cancer cells while increasing the response to chemotherapeutic drugs like anthracyclines and other anti-cancer treatments [ 131 , 141 ].…”

Section: Combination Treatment Strategiesmentioning

confidence: 99%

Recent Advances in Nanoparticle-Based Co-Delivery Systems for Cancer Therapy

2022

View full text Add to dashboard Cite

Cancer therapies have advanced tremendously throughout the last decade, yet multiple factors still hinder the success of the different cancer therapeutics. The traditional therapeutic approach has been proven insufficient and lacking in the suppression of tumor growth. The simultaneous delivery of multiple small-molecule chemotherapeutic drugs and genes improves the effectiveness of each treatment, thus optimizing efficacy and improving synergistic effects. Nanomedicines integrating inorganic, lipid, and polymeric-based nanoparticles have been designed to regulate the spatiotemporal release of the encapsulated drugs. Multidrug-loaded nanocarriers are a potential strategy to fight cancer and the incorporation of co-delivery systems as a feasible treatment method has projected synergistic benefits and limited undesirable effects. Moreover, the development of co-delivery systems for maximum therapeutic impact necessitates better knowledge of the appropriate therapeutic agent ratio as well as the inherent heterogeneity of the cancer cells. Co-delivery systems can simplify clinical processes and increase patient quality of life, even though such systems are more difficult to prepare than single drug delivery systems. This review highlights the progress attained in the development and design of nano carrier-based co-delivery systems and discusses the limitations, challenges, and future perspectives in the design and fabrication of co-delivery systems.

show abstract

“…To overcome chemoresistance using RNAi therapy, the simultaneous co-delivery of two types of siRNAs and of siRNA with antitumor drugs may be required in the combination therapy of multidrug resistance cancer [ 89 ]. Doxorubicin (DOX) is a common chemotherapy medication used to treat many kinds of cancers, such as breast cancer, bladder cancer, and lymphoma.…”

Section: Co-delivery Of Sirna and Low-molecular-weight Antitumor Drugmentioning

confidence: 99%

Twenty Years of Research on Cyclodextrin Conjugates with PAMAM Dendrimers

Arima

2021

Pharmaceutics

View full text Add to dashboard Cite

Recently, the number of gene and oligonucleotide drugs are increasing. Of various drug delivery systems (DDSs) for gene and oligonucleotide drugs, few examples of the clinical application of polymer as drug carriers are known, despite development of the novel polymers has been progressing. Cyclodextrin (CD) conjugates with starburst polyamidoamine (PAMAM) dendrimer (CDEs), as a new type of polymer-based carriers, were first published in 2001. After that, galactose-, lactose-, mannose-, fucose-, folate-, and polyethyleneglycol (PEG)-appended CDEs have been prepared for passive and active targeting for gene, oligonucleotide, and low-molecular-weight drugs. PEG-appended CDE formed polypsuedorotaxanes with α-CD and γ-CD, which are useful for a sustained release system of gene and oligonucleotide drugs. Interestingly, CDEs were found to have anti-inflammatory effects and anti-amyloid effects themselves, which have potential as active pharmaceutical ingredients. Most recently, CDE is reported to be a useful Cas9-RNA ribonucleoproteins (Cas9 RNP) carrier that induces genome editing in the neuron and brain. In this review, the history and progression of CDEs are overviewed.

show abstract

The importance of co‐delivery of nanoparticle‐siRNA and anticancer agents in cancer therapy

Cited by 14 publications

References 137 publications

Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy

Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy

Recent Advances in Nanoparticle-Based Co-Delivery Systems for Cancer Therapy

Twenty Years of Research on Cyclodextrin Conjugates with PAMAM Dendrimers

Contact Info

Product

Resources

About